en.Wedoany.com Reported - Belgian particle accelerator technology company Ion Beam Applications S.A. (IBA) recently launched the Cyclone iKure in Louvain-la-Neuve, a dedicated cyclotron designed for the routine production of Astatine-211 (At-211). This equipment serves radiopharmaceutical manufacturers, research institutions, and healthcare providers, primarily addressing the challenges of isotope supply, production stability, and facility compatibility when targeted alpha therapy drugs transition from early-stage research to clinical-scale projects.
Targeted alpha therapy is emerging as a significant direction in precision oncology and the nuclear medicine industry. Its fundamental principle leverages alpha-emitting isotopes to release high-energy radiation over extremely short distances, enabling radiopharmaceuticals to act more precisely on tumor cells while reducing exposure to surrounding healthy tissue. At-211, due to its specific chemical properties and half-life, is considered a key isotope in related drug development. However, for such isotopes to transition from research validation to routine clinical use, the real bottleneck often lies not in the individual drug molecule itself, but in the stable, reproducible, and compliant production infrastructure. The Cyclone iKure introduced by IBA is specifically designed around the At-211 isotope workflow, employing an alpha beam irradiation approach. Its goal is to achieve production-grade At-211 output while reducing daily operational complexity and radiation exposure for personnel through automated processes. The equipment is designed with a compact footprint to adapt to limited site conditions, reducing the complexity and cost of site preparation. Simultaneously, the system design addresses CE marking requirements and regulatory compliance. Unlike past cyclotrons primarily serving the production of diagnostic imaging isotopes for PET and SPECT, the Cyclone iKure extends IBA's equipment portfolio into the production of therapeutic alpha isotopes. This signifies that nuclear medicine equipment suppliers are expanding from "diagnostic isotope equipment" towards "theranostic and therapeutic isotope equipment."
Product specifications indicate that the Cyclone iKure has an energy range of 28.5 to 29.5 MeV, a cyclotron body size of approximately 3 meters by 3 meters, a vault space requirement of approximately 6.5 meters by 6.5 meters by 3 meters, and utilizes a solid target system.
The market entry of such equipment primarily impacts the front end of the nuclear medicine supply chain. Current targeted alpha drug development involves multiple stages, including isotope production, radiochemistry, drug labeling, preclinical validation, clinical development, regulatory approval, manufacturing licensing, personnel training, and hospital application. A shortfall in any single link can impede the speed at which a drug moves from the laboratory to clinical projects. Without a stable source of At-211, research institutions struggle to establish a continuous trial rhythm, and hospitals and companies find it difficult to plan subsequent clinical application scenarios. IBA positions the Cyclone iKure as an industrial-scale At-211 production device and integrates it into the ACCELERATE.EU European At-211 value chain initiative and the strategy to explore a transatlantic At-211 production network with Framatome. This reflects that competition in nuclear medicine is extending from single-point drug development to encompass isotopes, equipment, sites, compliance, and regional supply networks. For healthcare institutions, the broader clinical adoption of targeted alpha therapy in the future depends not only on drug safety and efficacy but also on the stable supply of isotopes meeting quality requirements. For equipment manufacturers and radiopharmaceutical companies, dedicated cyclotrons, automated production processes, solid target systems, radiochemistry modules, and quality control capabilities will collectively form the key building blocks for the next wave of nuclear medicine infrastructure.
IBA states that the Cyclone iKure is developed based on its approximately four decades of cyclotron engineering experience, aiming to help radiopharmaceutical innovators and clinical institutions advance At-211 labeled drugs from early-stage projects to routine clinical application. As the global nuclear medicine industry continues to expand around therapeutic isotopes, cyclotrons, radiopharmaceutical production, and targeted alpha therapy will become high-barrier directions in healthcare engineering. Whether related equipment can achieve stable delivery and regionalized production networks will influence the industrialization pace of precision oncology in the next phase.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
